ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+28.27%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$138M
AUM Growth
+$138M
(-6.8%)
Cap. Flow
+$14.2M
Cap. Flow
% of AUM
10.33%
Top 10 Holdings %
Top 10 Hldgs %
57.7%
Holding
51
New
15
Increased
8
Reduced
16
Closed
8
Top Buys
| 1 |
Taysha Gene Therapies
TSHA
|
$12.1M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$7.65M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$2.8M |
| 4 |
HilleVax
HLVX
|
$2.79M |
| 5 |
Replimune Group
REPL
|
$2.57M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$5.17M |
| 2 |
argenx
ARGX
|
$4.9M |
| 3 |
Clene
CLNN
|
$3.73M |
| 4 |
GH Research
GHRS
|
$2.9M |
| 5 |
Roivant Sciences
ROIV
|
$2.22M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Taysha Gene Therapies
TSHA
$797M
| $12.1M | 8.11% | +3,827,926 | New | +$12.1M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $9.3M | 6.23% | 244,484 -53,112 | -18% | -$2.02M |
|
|
WHWK
3
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $8.95M | 6% | 1,849,402 | – | – |
|
4
Praxis Precision Medicines
PRAX
$958M
| $7.67M | 5.14% | 4,485,000 +235,000 | +6% | +$402K |
|
|
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $7.65M | 5.13% | +344,571 | New | +$7.65M |
|
6
Rocket Pharmaceuticals
RCKT
$354M
| $7.42M | 4.97% | 362,000 +55,806 | +18% | +$1.14M |
|
7
Ventyx Biosciences
VTYX
$171M
| $7.13M | 4.78% | 205,377 +58,059 | +39% | +$2.02M |
|
8
Disc Medicine
IRON
$2.07B
| $6.49M | 4.35% | 138,198 -1,302 | -0.9% | -$61.2K |
|
9
Kura Oncology
KURA
$686M
| $6.4M | 4.29% | 702,093 -7,025 | -1% | -$64.1K |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $6.23M | 4.18% | 418,000 -12,000 | -3% | -$179K |
|
11
Vaxcyte
PCVX
$4B
| $6.17M | 4.13% | 121,022 -1,144 | -0.9% | -$58.3K |
|
12
Immunovant
IMVT
$2.56B
| $4.95M | 3.32% | 129,000 -12,755 | -9% | -$490K |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.31M | 2.89% | 297,035 -2,806 | -0.9% | -$40.7K |
|
|
14
HilleVax
HLVX
$105M
| $3.64M | 2.44% | 270,319 +207,241 | +329% | +$2.79M |
|
15
Alkermes
ALKS
$4.78B
| $3.54M | 2.37% | 126,500 +81,811 | +183% | +$2.29M |
|
16
Viridian Therapeutics
VRDN
$1.5B
| $3.44M | 2.31% | 224,339 -368 | -0.2% | -$5.65K |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $3.37M | 2.26% | 122,341 -2 | -0% | -$55 |
|
|
18
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.8M | 1.87% | +94,000 | New | +$2.8M |
|
19
Terns Pharmaceuticals
TERN
$609M
| $2.79M | 1.87% | 555,260 -414,740 | -43% | -$2.09M |
|
|
20
Replimune Group
REPL
$422M
| $2.57M | 1.72% | +150,000 | New | +$2.57M |
|
21
EyePoint Pharmaceuticals
EYPT
$797M
| $2.4M | 1.61% | 300,128 -81,872 | -21% | -$654K |
|
|
IMA
22
ImageneBio, Inc. Common Stock
IMA
$150M
| $2.39M | 1.6% | 551,010 -6,990 | -1% | -$30.3K |
|
|
CNTA
23
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.09M | 1.4% | +323,349 | New | +$2.09M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $1.89M | 1.27% | 153,007 +47,193 | +45% | +$583K |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $1.88M | 1.26% | +15,500 | New | +$1.88M |
|